Home > Journals > Chirurgia > Past Issues > Chirurgia 2011 December;24(6) > Chirurgia 2011 December;24(6):353-6

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

CHIRURGIA

A Journal on Surgery


Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index

 

CASE REPORTS  


Chirurgia 2011 December;24(6):353-6

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

5-ALA guided surgery plus carmustine wafer implant and the Stupp regimen (radiotherapy and temozolomide) for the treatment of glioblastoma multiforme

De’Santi M. S. 1, Genovese M. 1, Amoroso E. 1, Manto A. 2, Piucci B. 3

1 Neurosurgery Unit “Umberto I” Hospital, Nocera Inferiore, Salerno, Italy 2 Neuroradiology Unit “Umberto I” Hospital, Nocera Inferiore, Salerno, Italy 3 Hospital Service of Pharmacology, “Umberto I” Hospital, Nocera Inferiore, Salerno, Italy


PDF  


Survival outcomes were observed for 10 patients with glioblastoma multiforme treated with 5-aminolevulinic-acid-(5-ALA)-guided surgery, carmustine wafer implants, and radiation with concomitant and adjuvant temozolomide. Tumour resection was guided by 5-ALA, a fluorescent tumour marker, to facilitate resection and improve outcomes. Carmustine wafer implants were implanted in the tumour cavity at surgery, and patients subsequently received radiation and temozolomide. Median time to progression was 13 months (range: 12-20), and median overall survival was 21 months (16-30). Combining different regimens may be an effective treatment option for patients with glioblastoma multiforme, who generally face a poor prognosis.

top of page

Publication History

Cite this article as

Corresponding author e-mail